ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Merck KGaA Builds Chinese Presence

by Alex Scott
November 25, 2013 | APPEARED IN VOLUME 91, ISSUE 47

Darmstadt, Germany-based Merck KGaA has unveiled plans to build a pharmaceutical plant in the Nantong Economic & Technological Development Area, near Shanghai, to produce medicines for treating diabetes, cardiovascular diseases, and thyroid disorders. The facility, which is set to cost $108 million, is slated to begin commercial production in 2017. “This new facility will become Merck Serono’s second-largest pharmaceutical manufacturing site in the world and will help ensure that our medicines will always be available to patients who rely on them,” says Allan Gabor, general manager and managing director for Merck Serono in China.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment